Windtree Therapeutics Return on Equity (ROE) Growth & History (WINT)
Windtree Therapeutics's return on equity was −26.70% for fiscal 2024.
View full Windtree Therapeutics company overviewWindtree Therapeutics annual return on equity history
| Fiscal year | Period ended | Return on equity | Change (percentage points) |
|---|---|---|---|
| 2024 | 2024-12-31 | −26.70% | +276.09 pp |
| 2023 | 2023-12-31 | −302.78% | −151.67 pp |
| 2022 | 2022-12-31 | −151.11% | −29.72 pp |
| 2021 | 2021-12-31 | −121.39% | −76.32 pp |
| 2020 | 2020-12-31 | −45.08% | −6.66 pp |
| 2019 | 2019-12-31 | −38.41% | +54.51 pp |
| 2018 | 2018-12-31 | −92.92% | — |
| 2015 | 2015-12-31 | −401.75% | −288.34 pp |
| 2014 | 2014-12-31 | −113.41% | +5.34 pp |
| 2013 | 2013-12-31 | −118.75% | +275.77 pp |
| 2012 | 2012-12-31 | −394.51% | +180.66 pp |
| 2011 | 2011-12-31 | −575.17% | — |
Windtree Therapeutics quarterly return on equity
| Fiscal quarter | Period ended | Return on equity | Change (percentage points) |
|---|---|---|---|
| Q2 2025 | 2025-06-30 | −153.01% | −25.87 pp |
| Q1 2025 | 2025-03-31 | −39.88% | −148.52 pp |
| Q4 2024 | 2024-12-31 | 38.42% | +133.20 pp |
| Q3 2024 | 2024-09-30 | −69.57% | −23.20 pp |
| Q2 2024 | 2024-06-30 | −127.14% | −56.28 pp |
| Q1 2024 | 2024-03-31 | 108.64% | +156.89 pp |
| Q4 2023 | 2023-12-31 | −94.79% | −24.12 pp |
| Q3 2023 | 2023-09-30 | −46.36% | −24.21 pp |
| Q2 2023 | 2023-06-30 | −70.85% | −6.57 pp |
| Q1 2023 | 2023-03-31 | −48.25% | −27.03 pp |
| Q4 2022 | 2022-12-31 | −70.66% | −42.26 pp |
| Q3 2022 | 2022-09-30 | −22.15% | −6.79 pp |
| Q2 2022 | 2022-06-30 | −64.28% | −13.84 pp |
| Q1 2022 | 2022-03-31 | −21.22% | −10.09 pp |
| Q4 2021 | 2021-12-31 | −28.40% | −18.14 pp |
| Q3 2021 | 2021-09-30 | −15.36% | −4.03 pp |
| Q2 2021 | 2021-06-30 | −50.44% | −37.99 pp |
| Q1 2021 | 2021-03-31 | −11.13% | −2.12 pp |
| Q4 2020 | 2020-12-31 | −10.26% | +1.26 pp |
| Q3 2020 | 2020-09-30 | −11.33% | +1.47 pp |
| Q2 2020 | 2020-06-30 | −12.45% | −1.83 pp |
| Q1 2020 | 2020-03-31 | −9.01% | +0.96 pp |
| Q4 2019 | 2019-12-31 | −11.52% | +37.64 pp |
| Q3 2019 | 2019-09-30 | −12.80% | — |
| Q2 2019 | 2019-06-30 | −10.62% | — |
| Q1 2019 | 2019-03-31 | −9.97% | — |
| Q4 2018 | 2018-12-31 | −49.17% | — |
| Q1 2016 | 2016-03-31 | −851.26% | −761.08 pp |
| Q4 2015 | 2015-12-31 | −77.30% | −33.14 pp |
| Q3 2015 | 2015-09-30 | −291.06% | −257.84 pp |
| Q2 2015 | 2015-06-30 | −478.50% | −454.36 pp |
| Q1 2015 | 2015-03-31 | −90.18% | −68.79 pp |
| Q4 2014 | 2014-12-31 | −44.16% | −7.49 pp |
| Q3 2014 | 2014-09-30 | −33.22% | +76.45 pp |
| Q2 2014 | 2014-06-30 | −24.14% | +41.53 pp |
| Q1 2014 | 2014-03-31 | −21.39% | +71.82 pp |
| Q4 2013 | 2013-12-31 | −36.67% | −3.18 pp |
| Q3 2013 | 2013-09-30 | −109.68% | −64.24 pp |
| Q2 2013 | 2013-06-30 | −65.67% | −47.35 pp |
| Q1 2013 | 2013-03-31 | −93.21% | −47.16 pp |
| Q4 2012 | 2012-12-31 | −33.49% | +110.07 pp |
| Q3 2012 | 2012-09-30 | −45.43% | +22.76 pp |
| Q2 2012 | 2012-06-30 | −18.32% | +87.71 pp |
| Q1 2012 | 2012-03-31 | −46.05% | — |
| Q4 2011 | 2011-12-31 | −143.56% | — |
| Q3 2011 | 2011-09-30 | −68.19% | — |
| Q2 2011 | 2011-06-30 | −106.03% | — |
Windtree Therapeutics return on equity trends
Over the last five fiscal years, Windtree Therapeutics's return on equity increased from −38.41% to −26.70%, a change of +11.72 percentage points. The latest reported quarter, Q2 2025, shows −153.01%.
What return on equity (ROE) means
Return on equity (ROE) measures how much net income a company generates relative to shareholders’ equity. It can help evaluate how efficiently equity capital is used, but unusually high or negative values may reflect leverage, losses, or a small equity base.
How return on equity is calculated
TickerStat calculates ROE as SEC-reported net income divided by average stockholders’ equity at the beginning and end of the fiscal period. Periods with missing or non-positive average equity are omitted. Quarterly ROE uses quarterly net income and is not annualized. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Windtree Therapeutics source filings ↗